In this inaugural episode of Decode - AI in Lifesciences and Healthcare, host Sriram Subramanian, Co-Founder and Co-CEO of ZoomRx sits down with Jeremy Sauer, VP of Strategy at Callio Therapeutics, to cut through the AI hype and identify where artificial intelligence will genuinely move the needle in life sciences.

Jeremy brings a uniquely broad perspective, having worked across management consulting, early-stage biotech, and large pharma. Drawing on his experience at Pfizer, Seagen, and now Callio, he shares candid insights on the "jagged frontier" of AI capabilities - what's possible today versus what still needs to be built.

Key Topics Discussed:

• The Reality Check: Why AI is fundamentally different from previous tech waves, and why pharma's enthusiasm this time feels different
• Low-Hanging Fruit: How operational applications like clinical protocol writing and competitive intelligence are already delivering value
• The Discovery Dream: Why the "AI-designed drug" remains years away, and what data challenges stand in the way
• Clinical Trials: Where AI can dramatically reduce the 1/3 of trial sites that never enroll a single patient
• Leading Through Transformation: Managing teams through existential uncertainty and the uncomfortable truth about automation
• The Organizational Challenge: Why decentralized experimentation beats appointing a Chief AI Officer (for now)
• The Ultimate Bottleneck: How poor preclinical models, not discovery, may be pharma's biggest AI opportunity

Notable Quote:

"The only way to win is to play the game. To ignore it and say 'I can do it faster on my own' is going to be the losing bet."

A must-listen for market research directors, clinical development leaders, and strategic decision-makers navigating the AI revolution in life sciences.